Quest Partners LLC Purchases Shares of 638 Harrow, Inc. (NASDAQ:HROW)

Quest Partners LLC purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 638 shares of the company’s stock, valued at approximately $29,000.

Several other large investors have also added to or reduced their stakes in HROW. nVerses Capital LLC bought a new stake in shares of Harrow during the second quarter valued at approximately $33,000. Allspring Global Investments Holdings LLC grew its position in shares of Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after buying an additional 2,048 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after acquiring an additional 227 shares in the last quarter. Hills Bank & Trust Co bought a new position in shares of Harrow in the 3rd quarter worth about $107,000. Finally, Huntington National Bank purchased a new position in Harrow during the 3rd quarter valued at about $164,000. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on HROW shares. Lake Street Capital upped their price objective on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, October 4th. B. Riley restated a “buy” rating and issued a $50.00 price target on shares of Harrow in a research note on Thursday, August 29th. Finally, Craig Hallum lifted their price objective on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

Harrow Trading Down 1.3 %

Shares of NASDAQ HROW opened at $41.91 on Monday. The firm’s 50 day moving average price is $47.61 and its 200-day moving average price is $34.69. Harrow, Inc. has a 52-week low of $8.86 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company has a market cap of $1.49 billion, a PE ratio of -44.59 and a beta of 0.76.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.